Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Italy / NCT06946381
Recruiting Observational

CAMpania PugliA bRanch Iliaco

NCT06946381 · tracked via the Priya Life Science Italy tracker
Sponsor
Federico II University
Phase
Observational
Started
2015-01-01
Last updated
2025-04-27

Condition(s) studied

Aortoiliac AneurysmIliac Aneurysm

Investigational drug(s) / intervention(s)

Evar

Evar: Branch Evar with the e-liac device

Study summary

Spontaneus Multicentric Observational registry to investigate the medium and long-term performances of the Iliac E-liac Branch Device from Artivion for treatment of Aortoiliac aneurysms in a real-world consecutive patients cohort.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * An aortoiliac or aortic aneurysm of surgical interest based on the most recent local guidelines treated with the E-liac stent-graft system, alone or in combination with other devices Exclusion Criteria: * Patient's refusal to be enrolled in the registry * Patient treated with devices not including the E-liac stent-graft system

Primary outcome measure(s)

  • Aneurysm related death — assessed after procedure at 30 days, 6 months, one year, two years, three years, four years, five years.
    Aneurysm related death
  • Procedure-related re intervention — assessed after procedure at 30 days, 6 months, one year, two years, three years, four years, five years
    Procedure-related re intervention

Trial sites (2)

FacilityCityRegionStatus
Azienda ospedaliero-universitaria consorziale policlinico di Bari Bari BA Recruiting
Azienda Ospedaliera Universitaria Federico II Naples Italy Recruiting

More Federico II University trials in Italy

Naples Federico II Intensive Cardiac Care Unit Registry (Naples FED2-ICCU Registry) Recruiting
The Role of NIchel and LTPs Sensitization in Functional Gastrointestinal Disorders: the NILT Study Recruiting
Evaluation of Adherence, Persistence and Efficacy of Treatment With Alirocumab 300mg in Italy Recruiting
The Potential Role of Compounds Derived From Ultra-processed Foods in Pathogenesis of Eosinophilic Esophagitis Recruiting
Characterization of Cardiovascular Risk Profile and Therapeutic Management in Patients With Type 2 Diabetes Mellitus in Italy Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06946381 on ClinicalTrials.gov ↗ ← All trials in Italy